blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...
blank Related links

Extract from the Register of European Patents

EP About this file: EP1573332

EP1573332 - DIAGNOSTICS AND THERAPEUTICS FOR DISEASES ASSOCIATED WITH HUMAN PHOSPHODIESTERASE 9A3 (PDE9A3) [Right-click to bookmark this link]
StatusThe application has been refused
Status updated on  24.06.2011
Database last updated on 06.07.2024
Most recent event   Tooltip24.06.2011Refusal of applicationpublished on 27.07.2011  [2011/30]
Applicant(s)For all designated states
Boehringer Ingelheim International GmbH
Binger Strasse 173
55216 Ingelheim am Rhein / DE
[2006/44]
Former [2005/37]For all designated states
Bayer HealthCare AG
51368 Leverkusen / DE
Inventor(s)01 / GOLZ, Stefan
Bückmannsmühle 46
45326 Essen / DE
02 / BRÜGGEMEIER, Ulf
Leysiefen 20
42799 Leichlingen / DE
03 / SUMMER, Holger
Katernberger Schulweg 3
42113 Wuppertal / DE
 [2005/37]
Application number, filing date03780058.826.11.2003
[2005/37]
WO2003EP13276
Priority number, dateEP2002002753009.12.2002         Original published format: EP 02027530
[2005/37]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2004053492
Date:24.06.2004
Language:EN
[2004/26]
Type: A1 Application with search report 
No.:EP1573332
Date:14.09.2005
Language:EN
The application published by WIPO in one of the EPO official languages on 24.06.2004 takes the place of the publication of the European patent application.
[2005/37]
Search report(s)International search report - published on:EP24.06.2004
ClassificationIPC:G01N33/573, A61K38/00, A61K38/43
[2005/37]
CPC:
G01N33/573 (EP)
Designated contracting statesAT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HU,   IE,   IT,   LI,   LU,   MC,   NL,   PT,   RO,   SE,   SI,   SK,   TR [2005/37]
Extension statesALNot yet paid
LTNot yet paid
LVNot yet paid
MKNot yet paid
TitleGerman:DIAGNOSTIK UND THERAPIE FÜR KRANKHEITEN, DIE MIT HUMANE PHOSPHODIESTERASE 9A3 (PDE9A3) ASSOZIIERT SIND[2005/37]
English:DIAGNOSTICS AND THERAPEUTICS FOR DISEASES ASSOCIATED WITH HUMAN PHOSPHODIESTERASE 9A3 (PDE9A3)[2005/37]
French:DIAGNOSTIC ET TRAITEMENT DE MALADIES ASSOCIEES A LA PHOSPHODIESTERASE 9A3 (PDE9A3) HUMAINE[2005/37]
Entry into regional phase11.07.2005National basic fee paid 
11.07.2005Designation fee(s) paid 
11.07.2005Examination fee paid 
Examination procedure11.07.2005Examination requested  [2005/37]
25.01.2008Despatch of a communication from the examining division (Time limit: M06)
23.07.2008Reply to a communication from the examining division
10.02.2011Cancellation of oral proceeding that was planned for 22.03.2011
04.03.2011Despatch of communication that the application is refused, reason: substantive examination [2011/30]
14.03.2011Application refused, date of legal effect [2011/30]
22.03.2011Date of oral proceedings (cancelled)
Divisional application(s)The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  25.01.2008
Fees paidRenewal fee
30.11.2005Renewal fee patent year 03
13.11.2006Renewal fee patent year 04
30.11.2007Renewal fee patent year 05
01.12.2008Renewal fee patent year 06
30.11.2009Renewal fee patent year 07
30.11.2010Renewal fee patent year 08
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court
See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Cited inInternational search[DX]US6350603  (LOUGHNEY KATE) [DX] 1-18,23 * examples 5-7 *;
 [X]  - GUIPPONI MICHEL ET AL, "Identification and characterization of a novel cyclic nucleotide phosphodiesterase gene (PDE9A) that maps to 21q22.3: Alternative splicing of mRNA transcripts, genomic structure and sequence", HUMAN GENETICS, BERLIN, DE, (199810), vol. 103, no. 4, ISSN 0340-6717, pages 386 - 392, XP002234379 [X] 1-18,23 * the whole document *

DOI:   http://dx.doi.org/10.1007/s004390050838
    [ ] - EMBL, (19980720), Database accession no. AF067225 [ ] * column A *
 [A]  - LOUGHNEY K ET AL, "Isolation and characterization of PDE10A, a novel human 3', 5'-cyclic nucleotide phosphodiesterase", GENE, ELSEVIER BIOMEDICAL PRESS. AMSTERDAM, NL, (19990624), vol. 234, no. 1, ISSN 0378-1119, pages 109 - 117, XP004176895 [A] 1-18,23 * abstract * * page 112, column R, paragraph 3 - page 114, column L, paragraph 1; figures 1,2 *

DOI:   http://dx.doi.org/10.1016/S0378-1119(99)00171-7
 [A]  - FRANCIS S H ET AL, "CYCLIC NUCLEOTIDE PHOSPHODIESTERASES: RELATING STRUCTURE AND FUNCTION", PROGRESS IN NUCLEIC ACID RESEARCH AND MOLECULAR BIOLOGY, ACADEMIC PRESS, US, (2000), vol. 65, ISSN 0079-6603, pages 1 - 52, XP000993322 [A] 1-18,23 * abstract * * page 39, paragraph 2 - paragraph L *

DOI:   http://dx.doi.org/10.1016/S0079-6603(00)65001-8
 [PX]  - RENTERO CARLES ET AL, "Identification and distribution of different mRNA variants produced by differential splicing in the human phosphodiesterase 9A gene.", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, &, (20030214), vol. 301, no. 3, ISSN 0006-291X, pages 686 - 692, XP002275440 [PX] 1-18,23 * abstract * * page 686, paragraph 1 - page 687, paragraph 1; figure 4 *

DOI:   http://dx.doi.org/10.1016/S0006-291X(03)00021-4
 [PA]  - WANG P ET AL, "Identification and characterization of a new human type 9 cGMP-specific phosphodiesterase splice variant (PDE9A5) - Differential tissue distribution and subcellular localization of PDE9A variants", GENE: AN INTERNATIONAL JOURNAL ON GENES AND GENOMES, ELSEVIER SCIENCE PUBLISHERS, BARKING, GB, (20030918), vol. 314, ISSN 0378-1119, pages 15 - 27, XP004460836 [PA] 1-18,23 * the whole document *

DOI:   http://dx.doi.org/10.1016/S0378-1119(03)00733-9
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.